Success Metrics

Active Trials
14(88%)

Phase Distribution

Ph early_phase_1
1
6%
Ph phase_1
3
19%
Ph phase_3
3
19%
Ph phase_2
9
56%

Phase Distribution

4

Early Stage

9

Mid Stage

3

Late Stage

Phase Distribution16 total trials
Early Phase 1First-in-human
1(6.3%)
Phase 1Safety & dosage
3(18.8%)
Phase 2Efficacy & side effects
9(56.3%)
Phase 3Large-scale testing
3(18.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

14

trials recruiting

Total Trials

16

all time

Status Distribution
Active(15)
Terminated(1)

Detailed Status

Recruiting10
Active, not recruiting4
Withdrawn1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
14
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (6.3%)
Phase 13 (18.8%)
Phase 29 (56.3%)
Phase 33 (18.8%)

Trials by Status

withdrawn16%
recruiting1063%
active_not_recruiting425%
not_yet_recruiting16%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT06124157Phase 2

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
NCT06317662Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Recruiting
NCT05602194Phase 3

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

Recruiting
NCT03959085Phase 3

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Recruiting
NCT03007147Phase 3

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT02981628Phase 2

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Recruiting
NCT06390319Phase 2

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Recruiting
NCT05761171Phase 2

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Active Not Recruiting
NCT05292664Phase 1

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Recruiting
NCT05581030Phase 1

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Recruiting
NCT07072585Phase 2

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Not Yet Recruiting
NCT03117751Phase 2

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active Not Recruiting
NCT05192889Phase 1

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Active Not Recruiting
NCT04546399Phase 2

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
NCT03719105Early Phase 1

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Recruiting
NCT06210750Phase 2

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Withdrawn

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16